நுரையீரல் நோய்கள் மற்றும் சிகிச்சை இதழ்

Inhaled Drug Particle Dissolution and Absorption in the Lungs

Abstract

Basanth Bastola

Dry powder inhalation therapy has been shown to be effective in treating localised lung diseases such as asthma, COPD, cystic fibrosis, and lung infections. The physicochemical nature and aerosol performance of powder particles are determined in vitro for dry powder formulations. There is a well-established relationship between particle properties (size, shape, surface morphology, porosity, solid state nature, and surface hydrophobicity) and aerosol performance of an inhalable dry powder formulation. In contrast to oral formulations, there is no standard dissolution method for assessing the dissolution behaviour of inhalable dry powder particles in the lungs. This review focuses on different dissolution systems and absorption models used to evaluate dry powder formulations. It includes an overview of airway epithelium as well as barriers to development. an in vitro dissolution method for inhaled dry powder particles, fine particle dose collection methods, various in vitro dissolution testing methods developed for dry powder particles, and models commonly used to study inhaled drug absorption.